Evidence map›Paper›PMID 42717324›Full record

ArticleBMC nephrology2026

Characterization of pediatric patients receiving erythropoiesis-stimulating agents for management of anemia of chronic kidney disease in the UK and US: a feasibility assessment using retrospective chart review.

Sally Mountcastle, Keele Wurst, Alice Rouleau, Neil R Brett, Jennifer McKenzie, Justyna Amelio, Kathy Fraeman, Jake Hunnicutt, Susanna Cuadripani, David Webb and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sally Mountcastle *GSK, Collegeville, PA, USA.
Keele Wurst *GSK, Collegeville, PA, USA.
Alice RouleauPPD, Part of Thermo Fisher Scientific, Paris, France.
Neil R BrettPPD, Part of Thermo Fisher Scientific, Montreal, Quebec, Canada.
Jennifer McKenzie *GSK, Collegeville, PA, USA.
Justyna Amelio *GSK, Stevenage, Hertfordshire, UK.
Kathy FraemanPPD, Part of Thermo Fisher Scientific, Bethesda, MD, USA.
Jake Hunnicutt *GSK, Collegeville, PA, USA.
Susanna CuadripaniGSK, Stevenage, Hertfordshire, UK.
David Webb *GSK, 79 New Oxford Street, London, WC1A 1DG, UK.
Amrit KaurManchester University NHS Foundation Trust, Manchester, UK.
Rukshana ShroffUCL Great Ormond Street Institute of Child Health, London, UK.
Eleonora Staines UriasGSK, 79 New Oxford Street, London, WC1A 1DG, UK.
Anna RichardsGSK, 79 New Oxford Street, London, WC1A 1DG, UK. anna.x.richards@gsk.com.
Thomas F Hiemstra *GSK, Stevenage, Hertfordshire, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnemia is a common complication of chronic kidney disease (CKD). We evaluated the feasibility of collecting comprehensive data from medical charts for longitudinal assessment of anemia among pediatric patients receiving erythropoiesis-stimulating agents (ESAs) for anemia of CKD in the United Kingdom (UK) and United States (US).

methodsThis retrospective chart review study used an electronic case report form to collect data from medical records of pediatric patients treated with an ESA (as either an incident or a prevalent patient) from January 1, 2017-December 31, 2018. Consecutive chart reviews were conducted from November 1-December 20, 2021. Data collected included clinical characteristics, disease, and treatment management.

resultsOf 50 patients enrolled, 36 (72.0%) and 14 (28.0%) were from the UK and US, respectively; median (interquartile range) age was 9.0 (4.0-11.0) years, 22 (44.0%) were female and 28 (56.0%) were male. Median follow-up was 52.1 weeks. The most common primary CKD etiology was congenital anomalies of the kidney/urinary tract (n = 14, 28.0%). Twenty-three (46.0%) patients received dialysis at the index date and eight (16.0%) had a kidney transplant post-index date. Twenty-eight (56.0%) patients received iron treatment with their index-line ESA. The mean (standard deviation) baseline hemoglobin level was 10.0 (2.0) g/dL. Twenty adverse events (AEs) were recorded in nine (18.0%) patients; all were serious and no inference was sought for attributability to treatment.

conclusionsThis study demonstrates feasibility of retrospectively extracting clinical characteristics, treatment history, and AEs from medical charts of pediatric patients with anemia of CKD.

Indexed as

AnemiaHematinicsRenal Insufficiency, ChronicChildChild, PreschoolFeasibility StudiesFemaleHumansMaleRetrospective StudiesUnited KingdomUnited StatesHematinicsAnemia of chronic kidney diseaseClinical managementErythropoiesis-stimulating agentsPediatric patients

Identifiers

PMID42717324
PMCPMC13560262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.